Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04649060
Title Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma (LIGHTHOUSE)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Oncopeptides AB
Age Groups: senior | adult
Covered Countries ESP | DEU

No variant requirements are available.